###begin article-title 0
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4 </italic>
###xml 11 18 11 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5 </italic>
CYP3A4 and CYP3A5 genotyping by Pyrosequencing
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 282 289 282 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4 </italic>
###xml 290 299 290 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4*1B</italic>
###xml 301 309 301 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4*2</italic>
###xml 315 323 315 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4*3</italic>
###xml 329 336 329 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5 </italic>
###xml 337 347 337 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*3C </italic>
###xml 351 359 351 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*6</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human cytochrome P450 3A enzymes, particularly CYP3A4 and CYP3A5, play an important role in drug metabolism. CYP3A expression exhibits substantial interindividual variation, much of which may result from genetic variation. This study describes Pyrosequencing assays for key SNPs in CYP3A4 (CYP3A4*1B, CYP3A4*2, and CYP3A4*3) and CYP3A5 (CYP3A5*3C and CYP3A5*6).
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
Genotyping of 95 healthy European and 95 healthy African volunteers was performed using Pyrosequencing. Linkage disequilibrium, haplotype inference, Hardy-Weinberg equilibrium, and tag SNPs were also determined for these samples.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4*1B </italic>
###xml 75 84 75 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4*2 </italic>
###xml 131 140 131 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4*3 </italic>
###xml 220 230 220 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*3C </italic>
###xml 275 284 275 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*6 </italic>
CYP3A4*1B allele frequencies were 4% in Europeans and 82% in Africans. The CYP3A4*2 allele was found in neither population sample. CYP3A4*3 had an allele frequency of 2% in Europeans and 0% in Africans. The frequency of CYP3A5*3C was 94% in Europeans and 12% in Africans. No CYP3A5*6 variants were found in the European samples, but this allele had a frequency of 16% in the African samples. Allele frequencies and haplotypes show interethnic variation, highlighting the need to analyze clinically relevant SNPs and haplotypes in a variety of ethnic groups.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 159 167 <span type="species:ncbi:9606">patients</span>
Pyrosequencing is a versatile technique that could improve the efficiency of SNP analysis for pharmacogenomic research with the ultimate goal of pre-screening patients for individual therapy selection.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 195 201 195 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5</italic>
###xml 203 209 203 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A7</italic>
###xml 211 217 211 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4</italic>
###xml 223 230 223 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A43</italic>
###xml 659 660 659 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 661 662 661 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human cytochrome P450 3A (CYP3A) subfamily of enzymes plays an important role in drug metabolism. The four CYP3A genes lie within a 218 kb region of chromosome 7q22.1 in the following order: CYP3A5, CYP3A7, CYP3A4, and CYP3A43. CYP3A enzymes, primarily CYP3A4 and CYP3A5, catalyze the metabolism of a multitude of exogenous and endogenous compounds. As the most abundant group of CYPs in the liver and small intestine, CYP3A enzymes strongly affect the oral bioavailability and clearance of many drugs, and it is estimated that CYP3A enzymes are involved in the metabolism of over half of the drugs currently approved by the Food and Drug Administration [1-4].
###end p 11
###begin p 12
###xml 173 174 173 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 175 176 175 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 208 214 208 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A </italic>
###xml 419 420 419 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
Interindividual variation in CYP3A expression is substantial. Protein expression in liver and small intestine varies up to 40-fold, leading to variation in drug metabolism [2,5]. Genetic variation within the CYP3A genes may contribute to interindividual variability in drug metabolism. It has been suggested that approximately 90% of inter-individual differences in hepatic CYP3A activity are due to genetic variation [6]. Single nucleotide polymorphisms (SNPs) are the most common form of genetic variation in the CYP3A genes.
###end p 12
###begin p 13
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4*1B </italic>
###xml 60 67 60 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4 </italic>
###xml 68 69 68 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 105 115 105 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4*1B </italic>
###xml 240 250 240 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4*1B </italic>
###xml 326 327 326 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 328 329 328 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 368 381 368 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4*1A/*1A</italic>
###xml 476 478 476 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 203 211 <span type="species:ncbi:9606">patients</span>
CYP3A4*1B is a 5' untranslated region -392A>G transition in CYP3A4 [7]. A number of associations between CYP3A4*1B and clinical phenotypes have been found. Rebbeck et al. have shown that prostate cancer patients are more likely to have the CYP3A4*1B allele than healthy controls, and this has been confirmed in other studies [7-9]. Additionally, homozygous wild-type (CYP3A4*1A/*1A) individuals have an increased risk for developing leukemia after epipodophyllotoxin therapy [10].
###end p 13
###begin p 14
###xml 75 82 75 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4 </italic>
###xml 88 97 88 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4*2 </italic>
###xml 101 109 101 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4*3</italic>
###xml 111 120 111 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4*2 </italic>
###xml 186 195 186 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 227 236 227 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4*2 </italic>
###xml 320 322 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 325 334 325 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4*3 </italic>
###xml 547 549 547 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
Relatively little is known about the effects of the other commonly studied CYP3A4 SNPs, CYP3A4*2 and CYP3A4*3. CYP3A4*2 is a SNP in exon 7 (15713T>C) that results in a Ser222Pro change. In vitro kinetic studies have shown that CYP3A4*2 has a 6-to 9-fold reduced intrinsic clearance for nifedipine compared to wild-type [11]. CYP3A4*3 is a 1334T>C transition causing a Met445Thr change. Although this SNP occurs within a conserved region, no difference in testosterone, progesterone, or 7-benzyloxy-4(trifluoromethyl)coumarin metabolism was found [12].
###end p 14
###begin p 15
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*3C </italic>
###xml 68 75 68 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5 </italic>
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 278 288 278 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*3C </italic>
###xml 360 369 360 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*1 </italic>
###xml 402 404 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 536 543 536 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5 </italic>
###xml 629 631 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
CYP3A5*3C is an IVS3-237A>G (6986A>G) transition within intron 3 of CYP3A5 [13]. This transition creates an alternative splice site in the pre-mRNA, leading to the production of aberrant mRNA with a premature stop codon [13]. This SNP leads to polymorphic expression of CYP3A5. CYP3A5*3C homozygotes lack CYP3A5 expression, while individuals with at least one CYP3A5*1 wild-type allele express CYP3A5 [13]. Polymorphic expression of CYP3A5 may account for some of the interindividual variation in clearance of CYP3A substrates. Indeed, CYP3A5 genotype is predictive of tacrolimus doses for lung and kidney transplant recipients [14,15].
###end p 15
###begin p 16
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*6 </italic>
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 231 240 231 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*6 </italic>
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
CYP3A5*6 is a 14690G>A synonymous mutation that causes the formation of a splice variant mRNA. Exon 7 is deleted, resulting in a frameshift and a truncated protein [13]. Very little is known about the effects of this SNP, although CYP3A5*6 was found to have no effect on midazolam clearance in a small sample size [16].
###end p 16
###begin p 17
###xml 212 219 212 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4 </italic>
###xml 223 230 223 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5 </italic>
For further analysis of these SNPs and their relations to clinical outcomes, an accurate, rapid, and cost efficient method of SNP evaluation is needed. This study describes the use of Pyrosequencing to assay key CYP3A4 and CYP3A5 SNPs.
###end p 17
###begin title 18
Methods
###end title 18
###begin title 19
Genotyping
###end title 19
###begin p 20
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 300 302 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 364 365 364 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 788 789 788 789 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 836 838 836 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 931 932 931 932 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
PCR was performed on DNA from 95 healthy European volunteers and 95 healthy African volunteers, after IRB approval and written informed consent [17,18]. PCR primers were designed using Primer Express Version 2.0 (ABI, Foster City, CA, USA) and Pyrosequencing Primer SNP Design Version 1.01 software [19]. Primer sequences and PCR conditions are described in Table 1. PCR was carried out using 1-5 ng genomic DNA, 0.6 nmol each of forward and reverse oligonucleotide PCR primers (one of which is biotinylated) (Integrated DNA Technologies, Coralville, Iowa, USA) and 1X AmpliTaq Gold PCR Master Mix (Applied Biosystems, CA, USA), containing 255U (0.05 U/ml) AmpliTaq Gold DNA polymerase, Gene Amp PCR Gold Buffer (30 mmol/L Tris-HCL, 100 mmol/L KCl, pH 8.05), 400 mM dNTP and 5 mmol/L MgCl2. Pyrosequencing was carried out as described [20] using internal primer diluted in 1X Annealing Buffer (20 mmol/L Tris-Acetate, 2 mmol/L MgAc2), 2X Binding Wash Buffer II pH 7.6 (10 mmol/L Tris-HCL, 2M NaCl, 1 mmol/L EDTA, 0.1% Tween20), Streptavidin Sepharose Beads (Amersham Biosciences, Uppsala, Sweden), 0.2 M NaOH,70% Ethanol, and a PSQ HS96 SNP reagent kit (Pyrosequencing AB, Uppsala, Sweden). Samples were analyzed on a PSQ HS96A instrument with pyrosequencing software (Biotage, Uppsala, Sweden). A Tecan pipetting robot (Tecan, Research Triangle Park, NC, USA) was used for all of the steps apart from the addition and transfer of the sepharose beads.
###end p 20
###begin title 21
Statistics
###end title 21
###begin p 22
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
Pairwise linkage disequilibrium (|D'|), haplotype inference, and Hardy-Weinberg equilibrium were determined using the Polymorphism and Haplotype Analysis Suite [21,22]. Tag SNPs were determined using SNPtagger [23,24].
###end p 22
###begin title 23
Results and discussion
###end title 23
###begin p 24
###xml 73 74 73 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 123 133 123 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4*1B </italic>
###xml 199 208 199 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4*2 </italic>
###xml 281 290 281 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4*3 </italic>
###xml 370 380 370 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*3C </italic>
###xml 425 434 425 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*6 </italic>
###xml 588 598 588 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*3C </italic>
###xml 602 611 602 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*6 </italic>
Genotyping data from the European and African samples are shown in Table 2. All results are in Hardy-Weinberg equilibrium. CYP3A4*1B allele frequencies were 4% for Europeans and 82% for Africans. No CYP3A4*2 alleles were found in either the European or African population samples. CYP3A4*3 had an allele frequency of 2% in Europeans and 0% in Africans. The frequency of CYP3A5*3C was 94% in Europeans and 12% in Africans. No CYP3A5*6 variants were found in the European samples, but this allele had a frequency of 16% in the African samples. There were no individuals homozygous for both CYP3A5*3C and CYP3A5*6 in either population.
###end p 24
###begin p 25
###xml 4 11 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4 </italic>
###xml 15 22 15 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5 </italic>
###xml 172 173 172 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 830 840 830 840 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*3C </italic>
###xml 943 953 943 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4*1B </italic>
###xml 957 967 957 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*3C </italic>
The CYP3A4 and CYP3A5 genes lie in close proximity (136 kb) to one another on chromosome 7q22.1, so haplotypes were determined across both genes for each population (Table 3). In Europeans, haplotype 1 was the predominant haplotype, with a 90% frequency. Haplotypes 2, 3, and 5 were also observed, with frequencies of 5.5%, 1.8%, and 1%, respectively. Haplotype 4 was not observed, but it has an inferred frequency of 1.8%. The African population had five observed haplotypes: Haplotype 4 (57%), Haplotype 2 (15%), Haplotype 5 (12%), Haplotype 6 (11%), and Haplotype 7 (3%). Haplotype 1 was not observed, but it has an inferred frequency of 0.6%. No loci are significantly linked in either population (data not shown). In addition, no haplotype tag SNPs could be identified in either population. However, genotyping Europeans for CYP3A5*3C could be used to identify the haplotype of 95.5% of the population. Similarly, genotyping Africans for CYP3A4*1B and CYP3A5*3C could be used to identify the haplotype of 84% of the population.
###end p 25
###begin p 26
###xml 17 27 17 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4*1B </italic>
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 88 98 88 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4*1B </italic>
###xml 235 237 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 249 258 249 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4*2 </italic>
###xml 324 333 324 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4*2 </italic>
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 435 444 435 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4*3 </italic>
###xml 537 539 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
The frequency of CYP3A4*1B in Europeans (4%) is consistent with other studies [25]. The CYP3A4*1B frequency in Africans (82%) is much higher than in Europeans, and it is also higher than the 35-67% frequency seen in African Americans [25]. The rare CYP3A4*2 allele was not found in either of our population samples. To date CYP3A4*2 has only been described in a Finnish Caucasian population, with an allele frequency of 2.7% [11]. The CYP3A4*3 allele frequency in Europeans (2%) is consistent with frequencies reported in other studies [25].
###end p 26
###begin p 27
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*3C </italic>
###xml 76 86 76 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*3C </italic>
###xml 213 222 213 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*6 </italic>
###xml 270 279 270 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*6 </italic>
###xml 419 428 419 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*6 </italic>
###xml 513 515 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 516 518 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
CYP3A5*3C frequency shows dramatic interethnic variation. In Europeans, the CYP3A5*3C variant is the predominant allele (94% frequency), but this allele has a much lower frequency in the African population (12%). CYP3A5*6 frequency also shows interethnic variation. The CYP3A5*6 allele was not found in Europeans, but it was found in the African population at a frequency of 16%. Other studies have also failed to find CYP3A5*6 in Europeans, but this has been found in African Americans at a frequency of 13-16% [16,26].
###end p 27
###begin p 28
###xml 344 351 344 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4 </italic>
###xml 372 379 372 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5 </italic>
###xml 420 430 420 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in silico </italic>
Haplotype also shows interethnic variation. Haplotype 1 is the predominant haplotype in Europeans, with haplotypes 2-5 occurring at low frequencies. In contrast, haplotype 4 is the most common haplotype in Africans, and haplotypes 2, 5, and 6 all occur at frequencies greater than 10%. However, the presence of homozygous variants was rare for CYP3A4 in Europeans and for CYP3A5 in Africans. Consequently, the limits of in silico determining haplotype frequencies in these populations should be taken into account. Larger population studies are necessary for a more accurate understanding of CYP3A4-CYP3A5 haplotypes. Interethnic variation highlights the need to analyze clinically relevant SNPs and haplotypes in a variety of ethnic groups. An understanding of the genetic variation that exists in various populations will aid in tailoring health care to different populations.
###end p 28
###begin title 29
Conclusion
###end title 29
###begin p 30
###xml 104 111 104 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4 </italic>
###xml 115 122 115 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5 </italic>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 928 936 <span type="species:ncbi:9606">patients</span>
Restriction fragment length polymorphism (RFLP) is the predominant method of SNP analysis used to assay CYP3A4 and CYP3A5 SNPs in previous studies [14,27]. Pyrosequencing offers several advantages over RFLP. For RFLP analysis, a SNP must alter a restriction enzyme cutting site. This limitation precludes many SNPs from RFLP analysis. Pyrosequencing assays can be designed for the vast majority of SNPs, making it a versatile alternative. Pyrosequencing also requires less time than RFLP. Post-PCR, Pyrosequencing steps take approximately 30 minutes for 96 samples, whereas enzyme digestion (1-2 h) and gel electrophoresis for RFLP take significantly longer. Additionally, Pyrosequencing assays are readily transferable to any lab with the appropriate equipment and require no on-site optimization. This procedure could improve the efficiency of SNP analysis for pharmacogenomic research with the ultimate goal of pre-screening patients for individual therapy selection.
###end p 30
###begin title 31
Competing interests
###end title 31
###begin p 32
The author(s) declare that they have no competing interests.
###end p 32
###begin title 33
Authors' contributions
###end title 33
###begin p 34
AG performed the experimental analysis and drafted the manuscript. AAG, HLM and SM interpreted the results. HLM and SM conceived of the study design and implementation and helped draft the manuscript. All authors read and approved the final manuscript.
###end p 34
###begin title 35
Pre-publication history
###end title 35
###begin p 36
The pre-publication history for this paper can be accessed here:
###end p 36
###begin p 37

###end p 37
###begin title 38
Acknowledgements
###end title 38
###begin p 39
This work was supported by the NIH Pharmacogenetics Research Network (U01 GM63340); , the General Clinical Research Center (P30 CA091842-01), R21 CA102461-01, and P01 CA101937-01. The authors thank Hilary Kannall, Christi Ralph and Chris Rose for technical assistance, and Derek Van Booven for computational expertise. This data has been deposited in the Phamacogenetics Knowledge Base .
###end p 39
###begin article-title 40
###xml 30 35 <span type="species:ncbi:9606">human</span>
Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians
###end article-title 40
###begin article-title 41
###xml 70 75 <span type="species:ncbi:9606">human</span>
Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism
###end article-title 41
###begin article-title 42
###xml 79 82 <span type="species:ncbi:10116">rat</span>
###xml 87 92 <span type="species:ncbi:9606">human</span>
Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues
###end article-title 42
###begin article-title 43
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human drug metabolizing cytochromes P450
###end article-title 43
###begin article-title 44
Cyclosporine and liver transplantation: will the midazolam test make blood level monitoring obsolete?
###end article-title 44
###begin article-title 45
Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method
###end article-title 45
###begin article-title 46
Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4
###end article-title 46
###begin article-title 47
###xml 107 115 <span type="species:ncbi:9606">patients</span>
Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients
###end article-title 47
###begin article-title 48
###xml 67 70 <span type="species:ncbi:9606">men</span>
CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia
###end article-title 48
###begin article-title 49
Association of CYP3A4 genotype with treatment-related leukemia
###end article-title 49
###begin article-title 50
CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity
###end article-title 50
###begin article-title 51
Identification and functional characterization of eight CYP3A4 protein variants
###end article-title 51
###begin article-title 52
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
###end article-title 52
###begin article-title 53
Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients
###end article-title 53
###begin article-title 54
###xml 48 56 <span type="species:ncbi:9606">patients</span>
Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms
###end article-title 54
###begin article-title 55
###xml 153 156 <span type="species:ncbi:9606">men</span>
###xml 161 166 <span type="species:ncbi:9606">women</span>
Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women
###end article-title 55
###begin article-title 56
Ethnic differences in catechol O-methyltransferase pharmacogenetics: frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or South-west Asian individuals
###end article-title 56
###begin article-title 57
Thiopurine methyltransferase alleles in British and Ghanaian populations
###end article-title 57
###begin article-title 58
Pyrosequencing primer design
###end article-title 58
###begin article-title 59
Pharmacogenetic analysis of clinically relevant genetic polymorphisms
###end article-title 59
###begin article-title 60
Caution on pedigree haplotype inference with software that assumes linkage equilibrium
###end article-title 60
###begin article-title 61
Polymorphism and Haplotype Analysis Suite
###end article-title 61
###begin article-title 62
Efficient selective screening of haplotype tag SNPs
###end article-title 62
###begin article-title 63
SNPtagger
###end article-title 63
###begin article-title 64
###xml 33 38 <span type="species:ncbi:9606">human</span>
Genetic contribution to variable human CYP3A-mediated metabolism
###end article-title 64
###begin article-title 65
The genetic determinants of the CYP3A5 polymorphism
###end article-title 65
###begin article-title 66
The CYP3A4*1B variant is related to the onset of puberty, a known risk factor for the development of breast cancer
###end article-title 66
###begin title 67
Figures and Tables
###end title 67
###begin p 68
###xml 55 62 55 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4 </italic>
###xml 66 73 66 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5 </italic>
Primer sequence, PCR and Pyrosequencing conditions for CYP3A4 and CYP3A5 SNP analysis.
###end p 68
###begin p 69
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>a</italic></sup>
a* = biotin molecule attached
###end p 69
###begin p 70
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>b</italic></sup>
bF = forward primer
###end p 70
###begin p 71
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>c</italic></sup>
cR = reverse primer
###end p 71
###begin p 72
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d </italic>
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>d </italic></sup>
d Simplex entry nucleotide information for Pyrosequencing
###end p 72
###begin p 73
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">e</sup>
eAssays on reverse complement strand
###end p 73
###begin p 74
###xml 36 43 36 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4 </italic>
###xml 47 54 47 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5 </italic>
Genotype and allele frequencies for CYP3A4 and CYP3A5 SNPs in European and African populations. Figures in brackets are 95% confidence intervals.
###end p 74
###begin p 75
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a </italic>
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>a </italic></sup>
a n = number of passed samples out of 95 samples tested
###end p 75
###begin p 76
###xml 23 30 23 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4 </italic>
###xml 34 40 34 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5</italic>
Haplotype analyses for CYP3A4 and CYP3A5.
###end p 76
###begin p 77
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a </italic>
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>a </italic></sup>
a inferred frequency
###end p 77

